Transcripts NKGen Biotech, Inc.

Equities

End-of-day quote Nasdaq Other stock markets 23:00:00 04/06/2024 BST			5-day change	1st Jan Change
1.45 ^USD	+0.69%		-13.17%	-47.27%

06-03	NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	CI
05-23	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	CI

No results for this search